Zhen Gu’s research team constructed alendronate (Ald) targeting modification and platelet membrane-coated nanoparticulate platform for targeted delivery of BTZ at the myeloma site based on the bone microenvironment and myeloma cell sequential targeting strategy (Hu et al., 2016). Here, CASC3 is linked to plasma cell myeloma.